Novo Nordisk (NVO) stock news

Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s

As Novo works to turn itself around, some analysts say Lilly has advantages that could help it maintain its position at the top of the obesity drug market.

Pharma stock soars 150% on injectables deal with Wegovy maker Novo

Shares in Swedish microcap stock Nanexa more than doubled after the drug-delivery group revealed a licensing deal with European pharma giant Novo Nordisk.

Novo defends diversification push as CEO eyes deals beyond obesity

Novo CEO Mike Doustdar told CNBC that it is considering M&A opportunities as it faces growing competition in the weight-loss market.

Novo Nordisk’s stock tumbles as doubts persist about Ozempic maker’s strategy

The drugmaker, best known for developing weight-loss and diabetes drugs, failed to excite investors hoping for a turnaround.

Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production

Eli Lilly is trying to catch up in the GLP-1 pill market to Novo, which got a head start in the space.

Novo’s Big 2030 Pitch Gets a Small Reception

Novo CEO Says Drugmaker Needs to “Rethink” its Obesity Strategy

From Novo Nordisk to ‘Novo’: A Strategic Reset Amid Rising Lilly Pressure

Novo CEO tells CNBC why drugmaker is rebranding, needs to 'rethink' obesity strategy

The Danish drugmaker called the changes the beginning of a new chapter for the company, which faces stiff competition from Eli Lilly.

Novo Nordisk is changing its name and its culture to try to compete in the GLP-1 diet-drug wars

The Danish drug giant behind Ozempic is competing with Eli Lilly in the market for weight-loss drugs.

Novo Nordisk (NVO)’s Pediatric Obesity Opportunity Faces a Bigger Test

Is Novo Nordisk Stock Still Too Cheap for Investors to Ignore?